This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Astellas makes $52/share cash offer for OSI Pharmaceuticals
22 Mar 2012
After over a year of attempting to enter into a friendly arrangement, Astellas Pharma has made a hostile bid to acquire top public biotech firm OSI Pharmaceuticals for $3.03bn in cash, or $52 a share (a 42% premium). In a written response on February 22, 2010, to Astellas' most recent oral proposal, OSI said the offer significantly undervalues the company and it is asking shareholders not to take any action. Astellas has filed a lawsuit to prevent OSI from conducting any activities, such as a "poison pill" plan that would interfere with the tender offer.
Payment Includes Cash
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?